Advertisement
GSK vs SNY
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Sanofi (SNY) Stock Comparison
Key Takeaways
- GlaxoSmithKline (GSK) has delivered stronger year-to-date gains of about 12% compared to Sanofi (SNY)'s roughly 4%, reflecting robust relative performance in recent market activity.
- GSK's trailing P/E ratio (price-to-earnings ratio) of 14.5 is notably lower than SNY's 20.2, indicating a more attractive valuation for income-focused investors.
- Both stocks trade around $110 billion in market capitalization, with diversified portfolios in vaccines and specialty medicines driving stability amid healthcare sector volatility.
- Recent pipeline approvals and regulatory nods have supported sentiment for both, though GSK exhibits greater momentum from respiratory and oncology advances.
- Tickeron's AI ratings highlight both as undervalued, but GSK scores higher on sales growth and profitability metrics.
- Diversified risk profiles position them well for defensive portfolios, with GSK showing superior one-year returns exceeding 50%.
Introduction
GlaxoSmithKline (GSK) and Sanofi (SNY) stand as pharmaceutical powerhouses, both emphasizing vaccines, specialty therapies, and global healthcare solutions. This stock comparison is particularly relevant for investors navigating the healthcare sector's blend of innovation-driven growth and defensive qualities. Traders seeking relative performance insights, dividend stability, or exposure to pipeline catalysts will find value in evaluating their business models, recent momentum, and market positioning. Amid broader market fluctuations, understanding these peers aids in portfolio diversification and trend assessment in a maturing pharma landscape.
GSK Overview and Recent Performance
GlaxoSmithKline (GSK), a UK-based leader in pharmaceuticals, focuses on vaccines, specialty medicines for oncology, respiratory conditions, and HIV, alongside general medicines for asthma and infections. In recent weeks, GSK shares have shown resilience, with year-to-date gains around 12% and one-year returns surpassing 50%, trading near $54 amid a 52-week range of $35–$62. Key influences include pipeline progress, such as additional approvals for depemokimab (a respiratory therapy) and Blenrep in new markets, alongside partial legal victories in licensing disputes. Upcoming quarterly earnings are anticipated to highlight sales growth, bolstering positive sentiment despite short-term pullbacks from mixed analyst notes. Low beta (0.35) underscores its defensive appeal.
SNY Overview and Recent Performance
Sanofi (SNY), headquartered in France, specializes in immunology, rare diseases, neurology, oncology, and vaccines, with standout products like Dupixent for inflammation. Recent market activity has seen SNY shares hover around $47 within a 52-week range of $43–$56, posting modest year-to-date returns of about 4% and one-year gains near 8%. Sentiment has been supported by strong Q1 earnings that beat EPS (earnings per share) expectations, CHMP (Committee for Medicinal Products for Human Use) recommendations for tolebrutinib in multiple sclerosis, and bond issuances for strategic flexibility. However, weaker sales metrics and bearish technical signals, like MACD crossovers, have tempered upside, with a low beta (0.32) affirming stability.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and sectors. These bots deliver real-time signals for copy trading, featuring annualized returns ranging from 15% to over 167%, win rates of 48%–88%, profit factors up to 11.7, and profit-to-drawdown ratios exceeding 20 in select cases. Styles vary from short-term momentum (e.g., 5–60 minute intraday) to longer-term trend following (up to 55 days), with multi-agent systems handling up to 25 tickers in areas like semiconductors, energy, and finance. Only the most suitable for prevailing conditions earn a spot, offering data-driven edges with risk controls like TP/SL corridors. Investors can explore these high performers to enhance strategies.
Head-to-Head Comparison
Both GSK and SNY operate diversified pharma models centered on vaccines and specialties, but GSK leans heavier into respiratory/immunology and oncology small molecules, while SNY emphasizes immunology (e.g., Dupixent collaborations) and rare diseases. Growth drivers differ: GSK's Shingrix and Arexvy vaccines fuel stronger revenue trajectories versus SNY's reliance on Dupixent amid patent risks. Recent momentum favors GSK with superior YTD and one-year gains, though both exhibit low volatility. Risk factors include regulatory hurdles and M&A (mergers and acquisitions) integration, with SNY facing softer profitability ratings. Sector exposure aligns in healthcare defensives, but market sentiment tilts toward GSK's valuation edge and pipeline catalysts.
Tickeron AI Verdict
Tickeron's AI tools currently lean toward GSK over SNY, citing its undervaluation, superior sales/profitability scores, and more consistent uptrend signals amid recent pipeline wins. While both show stability and low risk, GSK's stronger relative positioning and momentum suggest higher probability of near-term outperformance, balanced against SNY's earnings beats.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and SNY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 2 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).
- GSK’s FA Score: 2 green, 3 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 3 TA indicator(s) are bullish while SNY’s TA Score has 2 bullish TA indicator(s).
- GSK’s TA Score: 3 bullish, 5 bearish.
- SNY’s TA Score: 2 bullish, 8 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -4.14% price change this week, while SNY (@Pharmaceuticals: Major) price change was -3.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
GSK is expected to report earnings on Jul 28, 2026.
SNY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | SNY | GSK / SNY | |
| Capitalization | 103B | 101B | 102% |
| EBITDA | 10.1B | 8.52B | 119% |
| Gain YTD | 5.106 | -7.701 | -66% |
| P/E Ratio | 13.28 | 18.43 | 72% |
| Revenue | 32.8B | 47.4B | 69% |
| Total Cash | 3.44B | 5.54B | 62% |
| Total Debt | 19.1B | 20B | 96% |
GSK | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 41 | 100 | |
SMR RATING 1..100 | 27 | 71 | |
PRICE GROWTH RATING 1..100 | 51 | 60 | |
P/E GROWTH RATING 1..100 | 80 | 41 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as GSK (15). This means that SNY’s stock grew similarly to GSK’s over the last 12 months.
GSK's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (100). This means that GSK’s stock grew somewhat faster than SNY’s over the last 12 months.
GSK's SMR Rating (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (71). This means that GSK’s stock grew somewhat faster than SNY’s over the last 12 months.
GSK's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as SNY (60). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.
SNY's P/E Growth Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (80). This means that SNY’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | SNY | |
|---|---|---|
| RSI ODDS (%) | N/A | 20 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 46% | 3 days ago 54% |
| Momentum ODDS (%) | 3 days ago 43% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 56% | 3 days ago 47% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 50% |
| TrendMonth ODDS (%) | 3 days ago 58% | 3 days ago 43% |
| Advances ODDS (%) | 9 days ago 61% | 9 days ago 50% |
| Declines ODDS (%) | 3 days ago 54% | 3 days ago 49% |
| BollingerBands ODDS (%) | 3 days ago 78% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 39% | 3 days ago 55% |
Advertisement
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with NVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then NVS could also see price increases.